Synergy Names Chief Strategy Officer
This article was originally published in Scrip
Executive Summary
Synergy Pharmaceuticals Inc. has appointed Marino Garcia to the newly created role of executive vice president and chief strategy officer – effective immediately. Garcia has been senior vice president corporate development and part of the leadership team since he joined Synergy in 2014. Previously he was vice president of global business development at Aptalis Pharma (acquired by Forest Labs) and vice president of US commercial operations and new product development at Aspreva Pharmaceuticals (acquired by Vifor Pharmaceuticals). Earlier in his career, Garcia held various US and international leadership roles in companies like Eli Lilly & Co and Pfizer.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.